Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 3/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24483686 | 1.00 | ADRA1A (0.51) | ADRA1AEPHX2PRMT1FOLH1KDM4E | |
| SCHEMBL8280997 | 0.91 | FOLH1 (0.48) | ADRA1AEPHX2PRMT1FOLH1KDM4E | |
| SCHEMBL24709112 | 0.91 | FOLH1 (0.48) | ADRA1AEPHX2PRMT1FOLH1KDM4E | |
| SCHEMBL18488491 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R | |
| SCHEMBL21242702 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R | |
| SCHEMBL14819872 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R | |
| SCHEMBL24558463 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R | |
| SCHEMBL24558585 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R | |
| SCHEMBL21938093 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R | |
| SCHEMBL24558475 | 0.90 | GLP1R (0.54) | EPHX2FOLH1NOD1ALBGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067693-A1 | POLYPEPTIDES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20220204580-A1 | POLYPEPTIDES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204580-A1 | POLYPEPTIDES AND USES THEREOF | IAPP, IGFBP2, IGFBP4 | ADRA1A 3836/4885EPHX2 2673/4885PRMT1 708/4885 |
| US-20240067693-A1 | POLYPEPTIDES AND USES THEREOF | IAPP, IGFBP2, IGFBP4 | ADRA1A 3836/4885EPHX2 2673/4885PRMT1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.